Ipca's stature as a quality-driven pharmaceutical major, and therefore a dependable and dynamic partner continues to grow with each passing day - bringing it closer to its vision to be a Global generic player in all major developed and developing markets, through enhanced geographical reach and product expansions.

The company's dynamism and foresight is evident in its strong thrust on backward integration by manufacturing the APIs for many of its Finished Dosage Forms. Thus, ensuring cost competitiveness and reliability of supplies giving it a distinct advantage in the Pharmaceutical Industry. Ipca's facilities have been approved by most of the discerning regulatory authorities including UK-MHRA, Australia-TGA, South Africa-MCC and Brazil-ANVISA.

In the United Kingdom, Ipca's Finished Dosage Forms are already being sold. The company has already initiated dossier filings for several generic products backed up by a strong pipeline which will also be offered in EU countries and other developed nations.

Ipca has a strong International presence in Antibacterials, Pain Management, Lifestyle Therapeutic segments like Cardiovasculars, Antidiabetics, Psychotropics etc.

In Anti-Malarials, which has been a traditional strong hold, Ipca has kept pace with the latest concepts of Artemesenin based combination therapy (ACT) based on recommendations from International forums including WHO.

Gastroenterologicals, Cold and Cough Preparations, Dermatologicals are the other main segments.